So far, only 1 phase I/II clinical Treg trial is registered in which IL-2 is used to increase Treg cell numbers to assess safety of and efficacy of IL-2 to increase circulating Treg levels by 75% in patients with ischemic heart disease.94 Here, IL2 is linked to coronary artery disorder.